Literature DB >> 10389643

Antibiotic resistance problems with Helicobacter pylori.

T Alarcón1, D Domingo, M López-Brea.   

Abstract

Helicobacter pylori is very susceptible in vitro to most antibiotics, but when they are used in the clinical setting, eradication of the bacteria from the gastric mucosa is not obtained. Dual or triple therapy including two of the following antibiotics: amoxicillin, tetracycline, metronidazole or clarithromycin, plus a proton pump inhibitor, bismuth salt or ranitidine bismuth citrate is the most frequently used. Various in vitro susceptibility methods have been used: disk diffusion, agar dilution and Epsilometer test (E-test). Metronidazole resistance among H. pylori strains is now found worldwide, and resistance rates vary according to the population studied. It is higher in developing than in developed countries and it could reach 80-90% in Africa. The prevalence on clarithromycin resistance is much lower, usually below 10%, although very high values are reported in Peru. Infection with metronidazole- or clarithromycin-resistant H. pylori strains is correlated with treatment failure when using regimens including these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389643     DOI: 10.1016/s0924-8579(99)00051-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  33 in total

1.  PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates.

Authors:  T Alarcón; D Domingo; N Prieto; M López-Brea
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Mechanism of metronidazole resistance in Helicobacter pylori: comparison of the rdxA gene sequences in 30 strains.

Authors:  N M Solcà; M V Bernasconi; J C Piffaretti
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran.

Authors:  Tahereh Falsafi; Fatemeh Mobasheri; Farahnaz Nariman; Mehri Najafi
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

4.  Assessment of Helicobacter pylori gene expression within mouse and human gastric mucosae by real-time reverse transcriptase PCR.

Authors:  B Rokbi; D Seguin; B Guy; V Mazarin; E Vidor; F Mion; M Cadoz; M J Quentin-Millet
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

5.  Evaluation of clarithromycin resistance and cagA and vacA genotyping of Helicobacter pylori strains from the west of Ireland using line probe assays.

Authors:  K A Ryan; L J van Doorn; A P Moran; M Glennon; T Smith; M Maher
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Azithromycin in one week quadruple therapy for H pylori eradication in Iran.

Authors:  Shahrokh Mousavi; Jafar Toussy; Siamak Yaghmaie; Mehrdad Zahmatkesh
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 7.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Systematic identification of selective essential genes in Helicobacter pylori by genome prioritization and allelic replacement mutagenesis.

Authors:  A F Chalker; H W Minehart; N J Hughes; K K Koretke; M A Lonetto; K K Brinkman; P V Warren; A Lupas; M J Stanhope; J R Brown; P S Hoffman
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

9.  Mutational analysis of metronidazole resistance in Helicobacter pylori.

Authors:  Jill M Moore; Nina R Salama
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

10.  Three-dimensional quantitative structure-activity relationship and comparative molecular field analysis of dipeptide hydroxamic acid Helicobacter pylori urease inhibitors.

Authors:  Hetal Mishra; Abby L Parrill; John S Williamson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.